Beatson West of Scotland Cancer Centre | Clinical Trials Unit

Research site

(Unclaimed)

Location

Level 0, Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, Glasgow City, Scotland

Site insights

Top conditions

Top treatments

Atezolizumab

Pembrolizumab

Trastuzumab

Cisplatin

Capecitabine

Gemcitabine

Carboplatin

Paclitaxel

Platinum

Temozolomide

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

76 of 255 total trials

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)

An open-label, controlled, multi-site, interventional, 2-arm, Phase II trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy...

Enrolling

Metastatic Head and Neck Cancer

Recurrent Head and Neck Cancer

Biological: BNT113

Biological: Pembrolizumab

A Long-term Extension Study of PCI-32765 (Ibrutinib) (CAN3001)

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to i...

Invitation-only

Waldenstrom Macroglobulinemia

Follicular Lymphoma

Drug: Ibrutinib

A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

Phase 1 Part (Complete): Open-label, sequential dose escalation study of pelabresib in patients with previously treated Acute Leukemia, Myelodysplast...

Active, not recruiting

Bone Marrow Disease

Myelofibrosis

Drug: Ruxolitinib

Drug: Pelabresib (CPI-0610)

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA)

This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) thera...

Enrolling

Post-essential Thrombocythemia Myelofibrosis

Post-polycythemia Vera Myelofibrosis

Drug: Physician's Choice medications

Drug: Pacritinib

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (CUPISCO)

This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with p...

Active, not recruiting

Cancer of Unknown Primary Site

Drug: Atezolizumab

Drug: Bevacizumab

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (Glofit-GemOx) compared with rituxima...

Enrolling

Diffuse Large B-cell Lymphoma

Drug: Oxaliplatin

Drug: Tocilizumab

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

This is a Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with locally advanced squamous cell carcinoma of the head...

Enrolling

Squamous Cell Carcinoma of the Head and Neck

Drug: Tiragolumab

Drug: Carboplatin

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (Morpheus-panBC)

This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally...

Enrolling

Breast Cancer

Drug: Abemaciclib

Drug: Ribociclib

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (Krascendo 170)

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of divarasib combined with other anti-cancer therapies in pa...

Enrolling

Non-Small Cell Lung Cancer

Drug: Pembrolizumab

Drug: Carboplatin

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to...

Enrolling

Metastatic Cancer

Advanced Cancer

Drug: ART0380

Drug: Gemcitabine

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)

The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in particip...

Active, not recruiting

Non-small Cell Lung Cancer (NSCLC)

Drug: Tiragolumab

Drug: Durvalumab

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

This is a Phase III, double-blinded, placebo-controlled, randomized, multicenter study designed to evaluate the efficacy, safety, and pharmacokinetic...

Active, not recruiting

Melanoma

Drug: Atezolizumab Placebo

Drug: Cobimetinib

A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck (SKYSCRAPER-09)

The primary objective of this study is to evaluate the efficacy of atezolizumab plus tiragolumab and atezolizumab plus placebo as first-line (1L) tre...

Active, not recruiting

Squamous Cell Carcinoma of Head and Neck

Drug: Placebo

Drug: Tiragolumab

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation (RAMP 201)

This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Lo...

Active, not recruiting

Low Grade Ovarian Serous Adenocarcinoma

Ovarian Cancer

Drug: avutometinib (VS-6766) and defactinib

Drug: avutometinib (VS-6766)

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386 in combination with pembrolizumab in participants with pr...

Active, not recruiting

Melanoma

Carcinoma, Hepatocellular

Drug: E7386

Drug: Lenvatinib

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL)

This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine vs. investigator's choice chemotherapy in patients wit...

Active, not recruiting

Epithelial Ovarian Cancer

Peritoneal Cancer

Drug: Paclitaxel

Drug: Pegylated liposomal doxorubicin

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

A Phase Ib/II, open label, multi-center, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor ac...

Active, not recruiting

Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

Drug: Linagliptin

Drug: Cobimetinib

A Study of NX-1607 in Adults With Advanced Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in pa...

Enrolling

Triple Negative Breast Cancer (TNBC)

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Drug: Paclitaxel

Drug: NX-1607

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (INTRIGUE)

This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of ripretinib to sunitinib in GIST patients who prog...

Active, not recruiting

Gastrointestinal Stromal Tumors

Drug: Sunitinib

Drug: Ripretinib

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk...

Active, not recruiting

HER2-Positive Primary Breast Cancer

Residual Invasive Breast Cancer

Drug: DS-8201a

Drug: T-DM1